GLP-1 Weight-Loss Marketing for Medspas: What’s Actually Legal to Advertise in 2026

The question I get more than any other from medspa owners right now is some version of: “Can I still advertise semaglutide?” The honest answer is yes — but almost certainly not the way you were advertising it in 2023 and 2024. Between early 2025 and mid-2026, the FDA effectively shut down mass compounding of GLP-1s, the FTC took a telehealth weight-loss company to the woodshed over its ads, Google rewrote its healthcare advertising policy, and Meta tightened how health advertisers can target and talk. I’ve spent the past year keeping my medspa clients’ campaigns on the right side of all of it, and this post is the map I wish someone had handed me. It pairs with my broader medspa advertising compliance guide for 2026, which covers HIPAA, testimonials, and consent in more depth.

One caveat before we start: I’m a marketer, not a lawyer. Everything below is sourced and current as of July 2026, but regulations move fast in this category. Run your specific ad plans past a healthcare attorney licensed in your state.

The compounded semaglutide era is over

For two years, the entire medspa GLP-1 boom ran on compounded semaglutide, which was permitted only because the branded drugs were on the FDA’s shortage list. That window closed. The FDA resolved the tirzepatide shortage in December 2024, and per FDA’s declaratory order of February 21, 2025, the semaglutide shortage was declared resolved as well. Under the enforcement timeline FDA laid out with that order, 503A compounding pharmacies had to stop producing copies of semaglutide injection by April 22, 2025, and 503B outsourcing facilities by May 22, 2025. The Outsourcing Facilities Association sued to block both determinations; federal courts denied preliminary injunctions in each case, and the deadlines held.

Then, on April 30, 2026, the FDA went further and proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, on a finding of no clinical need — with the public comment period running through late June 2026. If finalized, that closes the last large-scale compounding pathway for good.

What survives is narrow: a 503A pharmacy can still compound a patient-specific version when a prescriber documents a genuine clinical need for a modification — a different dosage form, an allergy to an inactive ingredient. What does not survive, in any form, is advertising “cheap compounded semaglutide” to the general public. If your website, Google Business Profile, or Instagram still says that, you are advertising a product the FDA has said should no longer be mass-produced, and you’re painting a target on your clinic.

What the FTC expects from your weight-loss claims

The clearest signal on ad claims came from the FTC’s action against telehealth provider NextMed. Per the FTC’s July 2025 complaint, NextMed advertised GLP-1 weight-loss programs at monthly prices of $138 or $188 without adequately disclosing that the price excluded the drug itself, the required lab work, and the medical consultation. The FTC also alleged fake Trustpilot reviews and before-and-after photos from people who were never NextMed patients. The FTC approved its final order in December 2025: a $150,000 payment earmarked for consumer refunds, plus ongoing requirements that any claim about average or typical results be backed by competent and reliable evidence, that pricing be truthful, and that review practices be clean.

Read that case as a checklist of what not to do, because every item on it is common in medspa marketing:

• Teaser pricing. If your ad says “$299/month,” that number must include — or clearly disclose the exclusion of — labs, consults, and the medication itself.
• Results claims. “Lose 20 lbs in 90 days” requires substantiation showing that’s a typical result for your actual patient population, per the FTC’s competent-and-reliable-evidence standard. Clinical trial numbers for Wegovy don’t automatically substantiate claims about your program.
• Testimonials and before/afters. They must be real patients, with written consent, and they can’t imply results are typical unless typical results back that up.

My own rule for clients: every number in an ad either comes from a citable source, comes from our own documented data, or gets cut. When I project outcomes in planning documents, I label them “est.” — and nothing labeled “est.” ever appears in a public-facing ad.

Google Ads: the October 2025 rules

Google updated its Healthcare and Medicines policy effective October 29, 2025. Per Google’s published policy update, prescription drug terms are now allowed in ad text and landing pages in limited, non-promotional contexts — things like public-health information or news. But the rule that actually matters for medspas didn’t loosen at all: keyword targeting of prescription drug terms (semaglutide, tirzepatide, Ozempic, Wegovy, Zepbound) still requires healthcare advertiser certification in the US, and Google recognizes LegitScript as its certification partner for this. No LegitScript certification, no drug-name keywords — and promotional use of drug names in your ad copy or landing pages remains restricted too.

Two practical notes from running these campaigns. First, LegitScript certification for a clinic typically takes an est. four to eight weeks from application to approval, so start before you need it — and be aware LegitScript will not certify operations built around compounded GLP-1 copies now that the shortage is resolved. Second, Google said enforcement of the October 2025 update would ramp over the following four to six weeks, with a warning at least seven days before account-level action. Don’t treat that warning window as breathing room; treat it as a fire alarm. I cover certification workarounds, compliant keyword structures, and “medical weight loss” campaign architecture in my full medspa Google Ads guide.

Meta: tighter targeting, tighter copy

Meta’s changes were quieter but bite just as hard. Since January 2025, Meta has classified advertiser domains within its health and wellness category — a medspa offering weight-loss injections typically lands in a restricted sub-category, which limits the lower-funnel conversion events you can optimize against. Practically, that means many medspas can no longer optimize GLP-1 campaigns for purchase or booking events off their own pixel data and have to rebuild around lead forms, calls, and landing-page views.

On the creative side, Meta’s ad standards prohibit ads that imply or attempt to generate negative self-perception to promote diet or weight-loss products. “Tired of hating what you see in the mirror?” is a policy violation, not a hook. And the political heat is rising: the Illinois Attorney General’s office sent Meta a formal letter in 2025 over misleading GLP-1 weight-loss drug ads on its platforms, which tells me platform enforcement will keep getting stricter, not looser.

State boards and drugmaker lawyers are the other enforcement layer

Federal agencies and ad platforms aren’t the only referees. Per law-firm analyses of the litigation wave, Novo Nordisk had filed more than 130 lawsuits across 40 states by mid-2025 against telehealth companies, compounding pharmacies, and clinics marketing compounded semaglutide, and both Novo Nordisk and Eli Lilly have been sending cease-and-desist letters directly to medspas and weight-loss clinics — typically demanding written certification within 10 to 14 days that the activity has stopped.

State medical and nursing boards, meanwhile, care about how the medicine is prescribed and administered, and your ads are evidence. If your ad promises “walk in, get your shot” with no mention of a medical evaluation, you’ve just advertised a violation of the good-faith-exam requirement most states impose. States with stricter compounding oversight — Florida, Texas, and New York among them, per legal-industry reporting following the FDA’s 2025 actions — issued their own follow-on guidance. Your prescriber structure, standing orders, and delegation rules are state-specific; your marketing has to match them.

What I’d actually run in 2026

Here’s the compliant playbook I build for clients, which sits inside my larger medspa marketing system:

1. Market the program, not the molecule. “Physician-supervised medical weight loss” is durable, honest, and platform-safe. The drug is one component of a program that includes evaluation, labs, monitoring, and lifestyle support — say that.
2. Go branded or go home. If you offer GLP-1s, offer FDA-approved branded products through legitimate prescribing and dispensing channels. Strip every reference to compounded copies from your site, profiles, and old boosted posts.
3. Get LegitScript certified if drug-name search terms matter to your funnel. Budget est. 4–8 weeks and real application effort.
4. Publish transparent pricing. All-in program pricing, clearly disclosed exclusions. This is both an FTC requirement and, in my experience, a conversion advantage — confused buyers don’t book.
5. Build educational content that answers real questions — “is compounded semaglutide still legal,” “what does medical weight loss include,” “Wegovy vs. Zepbound.” This is exactly the content AI assistants and Google’s AI results now pull answers from, which is why I fold it into answer engine optimization for every weight-loss client. Compliance content, ironically, is some of the best-performing acquisition content in this category right now.
6. Audit quarterly. The FDA’s 503B bulks-list proposal is still in motion as I write this, and platform policies shifted three times in eighteen months. Put a recurring compliance review on the calendar.

Want a second set of eyes on this for your clinic? Book a free strategy call or call/text me at +91 97297 12388.

Frequently asked questions

Can my medspa still advertise compounded semaglutide in 2026?

No — not as a marketed product. Per FDA’s February 2025 declaratory order and the enforcement deadlines that followed (April 22, 2025 for 503A pharmacies; May 22, 2025 for 503B facilities), mass-compounded copies of semaglutide are no longer permitted, and the FDA’s April 2026 proposal would remove GLP-1s from the 503B bulks list entirely. Narrow patient-specific compounding may still exist where a prescriber documents clinical need, but advertising compounded semaglutide to the public invites FDA attention, state board scrutiny, and cease-and-desist letters from Novo Nordisk or Eli Lilly.

Do I need LegitScript certification to run Google Ads for GLP-1 services?

If you want to bid on keywords containing prescription drug terms — semaglutide, Ozempic, Wegovy, Zepbound — yes. Google’s October 2025 Healthcare and Medicines policy update kept the certification requirement for drug-term keyword targeting in the US, with LegitScript as the recognized certifier. You can run “medical weight loss” campaigns without certification as long as your ads and landing pages avoid promotional use of drug names. Certification typically takes an est. 4–8 weeks.

Can I use before-and-after photos and testimonials in GLP-1 ads?

Only carefully. The FTC’s NextMed case (final order December 2025) targeted exactly this: photos and reviews from people who were never actual patients. Testimonials must come from real patients with documented written consent, must not misrepresent results, and cannot imply results are typical unless you have competent and reliable evidence that they are. On Meta, creative also can’t play on negative self-perception. HIPAA adds its own consent layer on top.

Can I advertise a monthly price like “$299/month”?

Yes, if it’s the truth — the whole truth. The FTC charged NextMed over advertised monthly prices that excluded the drug, required labs, and the prescribing consultation. If your advertised price doesn’t include everything a patient must pay to actually receive treatment, disclose the exclusions clearly and conspicuously in the ad itself, not just at checkout.

Can I name Wegovy or Zepbound in my marketing?

On your own website and organic content, yes — factually and without off-label claims, staying consistent with FDA-approved labeling. In paid channels it depends on the platform: on Google, promotional use of drug names in ads and drug-term keyword targeting require certification, while the October 2025 update permits limited non-promotional mentions. Trademark law also applies — describe what you prescribe, don’t imply a partnership with the manufacturer.

What happens if my ads get flagged — is my account banned immediately?

Usually not on the first offense. Google’s October 2025 policy rollout includes a warning at least seven days before account-level action, and Meta typically starts with ad-level rejections. But repeated violations compound fast, and a suspended ad account at a clinic doing paid acquisition is an existential problem. Fix the root cause — claims, landing pages, drug references — rather than resubmitting the same ad and hoping.